Prospective Grant of Exclusive License: “Anthrax Toxin Fusion Proteins and Uses Thereof,” “Anthrax Toxin Fusion Proteins and Related Methods,” and “Targeting Agents to the MHC Class I Processing Pathway with an Anthrax Toxin Fusion Protein”

Riepilogo

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the Food and Drug Administration and the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in "Anthrax toxin fusion proteins and uses thereof", by Leppla et al., issued as U.S. patent 5,591,631 on January 7, 1997; "Anthrax toxin fusion proteins and related methods" by Leppla et al., issued as U.S. patent 5,677,274 on October 14, 1997; and "Targeting agents to the MHC class I processing pathway with an anthrax toxin fusion protein" by Klimpel et al. filed internationally as PCT/US97/16452, and claiming priority to U.S. provisional patent application 60/025,270, filed September 17, 1996 to Avant Immunotherapeutics, Inc., which is located in Needham, MA. The patent rights in these inventions have been assigned to the United States of America. This technology is currently licensed to Avant Immunotherapeutics, Inc. on a non-exclusive basis in the area of immune diseases. The prospective exclusive license territory will be worldwide and the field of use may be limited to vaccines and immunotherapeutics for the prevention or